{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"MATINS","nct_id":"NCT03733990","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=matins-nct03733990. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Part I, Dose-escalation FP-1305 0.3 mg/kg is administered in Q3W intervals","label":"FP-1305 (bexmarilimab) 0.3 mg/kg","type":"EXPERIMENTAL"},{"description":"Part I and II, Dose-escalation FP-1305 1 mg/kg is administered in Q3W, Q2W or Q1W intervals","label":"FP-1305 (bexmarilimab) 1 mg/kg","type":"EXPERIMENTAL"},{"description":"Part I and II, Dose-escalation FP-1305 3 mg/kg is administered in Q3W, Q2W or Q1W intervals","label":"FP-1305 (bexmarilimab) 3 mg/kg","type":"EXPERIMENTAL"},{"description":"Part I and II, Dose-escalation FP-1305 10 mg/kg is administered in Q3W, Q2W or Q1W intervals","label":"FP-1305 (bexmarilimab) 10 mg/kg","type":"EXPERIMENTAL"},{"description":"Part I Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals","label":"FP-1305 (bexmarilimab) 0.1 mg/kg","type":"EXPERIMENTAL"},{"description":"Part II Dose-escalation FP-1305 30 mg/kg is administered in Q3W, Q2W or Q1W intervals","label":"FP-1305 (bexmarilimab) 30 mg/kg","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-10-31","type":"ACTUAL"},"conditions":["Cancer"],"enrollment":{"count":216,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"FP-1305 (bexmarilimab)","otherNames":["bexmarilimab"],"type":"BIOLOGICAL"}],"last_update":"2025-04-02","lead_sponsor":"Faron Pharmaceuticals Ltd","official_title":"A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-09-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Dose Limiting Toxicities (DLT) in the Trial Subjects.","timeFrame":"Up to one year"},{"measure":"Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)","timeFrame":"approximately 4 years and 9 months"},{"measure":"The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.","timeFrame":"approximately 4 years and 9 months"},{"measure":"The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.","timeFrame":"approximately 4 years and 9 months"}],"references":[{"citation":"Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmen M, Bono P. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5.","pmid":"38056464","type":"DERIVED"},{"citation":"Hollmen M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21(7):1207-1218. doi: 10.1158/1535-7163.MCT-21-0840.","pmid":"35500016","type":"DERIVED"},{"citation":"Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lonnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skytta T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmen M. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2.","pmid":"34078651","type":"DERIVED"}],"start_date":{"date":"2018-12-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)","url":"https://clinicaltrials.gov/study/NCT03733990"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/matins-nct03733990"}